JP2012525155A5 - - Google Patents

Download PDF

Info

Publication number
JP2012525155A5
JP2012525155A5 JP2012508789A JP2012508789A JP2012525155A5 JP 2012525155 A5 JP2012525155 A5 JP 2012525155A5 JP 2012508789 A JP2012508789 A JP 2012508789A JP 2012508789 A JP2012508789 A JP 2012508789A JP 2012525155 A5 JP2012525155 A5 JP 2012525155A5
Authority
JP
Japan
Prior art keywords
seq
cdr1
dvd
egfr
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012508789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525155A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/033231 external-priority patent/WO2010127284A2/en
Publication of JP2012525155A publication Critical patent/JP2012525155A/ja
Publication of JP2012525155A5 publication Critical patent/JP2012525155A5/ja
Withdrawn legal-status Critical Current

Links

JP2012508789A 2009-05-01 2010-04-30 二重可変ドメイン免疫グロブリンおよびこの使用 Withdrawn JP2012525155A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17471109P 2009-05-01 2009-05-01
US61/174,711 2009-05-01
PCT/US2010/033231 WO2010127284A2 (en) 2009-05-01 2010-04-30 Dual variable domain immunoglobulins and uses thereof

Publications (2)

Publication Number Publication Date
JP2012525155A JP2012525155A (ja) 2012-10-22
JP2012525155A5 true JP2012525155A5 (enExample) 2013-06-20

Family

ID=43032806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012508789A Withdrawn JP2012525155A (ja) 2009-05-01 2010-04-30 二重可変ドメイン免疫グロブリンおよびこの使用

Country Status (24)

Country Link
US (3) US20110263827A1 (enExample)
EP (1) EP2425010A4 (enExample)
JP (1) JP2012525155A (enExample)
KR (1) KR20120044294A (enExample)
CN (1) CN102459347A (enExample)
AR (1) AR076508A1 (enExample)
AU (1) AU2010242830C1 (enExample)
BR (1) BRPI1012193A2 (enExample)
CA (1) CA2760213A1 (enExample)
CL (1) CL2011002702A1 (enExample)
CO (1) CO6470824A2 (enExample)
CR (1) CR20110631A (enExample)
DO (1) DOP2011000333A (enExample)
EC (1) ECSP11011496A (enExample)
IL (1) IL215928A0 (enExample)
MX (1) MX2011011669A (enExample)
NZ (1) NZ596711A (enExample)
PE (1) PE20120813A1 (enExample)
RU (1) RU2011148913A (enExample)
SG (2) SG175427A1 (enExample)
TW (1) TW201042040A (enExample)
UY (1) UY32603A (enExample)
WO (1) WO2010127284A2 (enExample)
ZA (1) ZA201108704B (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4986370B2 (ja) 2000-12-22 2012-07-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Rgmおよびそのモジュレーターの用途
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CN102076355B (zh) 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2009256246B2 (en) 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AU2009268585C1 (en) 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
AU2010233994A1 (en) * 2009-04-07 2011-09-22 Roche Glycart Ag Bispecific anti-ErbB-3/anti-c-Met antibodies
PE20121647A1 (es) 2009-08-29 2012-12-31 Abbvie Inc Proteinas terapeuticas de union a dll4
TW201119673A (en) * 2009-09-01 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32948A (es) * 2009-10-15 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20120118002A (ko) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 rgm a 단백질에 대한 모노클로날 항체
SG10201501562VA (en) 2010-03-02 2015-04-29 Abbvie Inc Therapeutic dll4 binding proteins
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
JP2014509588A (ja) 2011-03-01 2014-04-21 アムジエン・インコーポレーテツド 二特異性結合剤
WO2012172521A1 (en) 2011-06-16 2012-12-20 Novartis Ag Soluble proteins for use as therapeutics
AU2012362370A1 (en) * 2011-12-30 2014-07-24 Abbvie Inc. Dual variable domain immunoglobulins against receptors
WO2013102042A2 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
PE20190907A1 (es) 2012-01-27 2019-06-26 AbbVie Deutschland GmbH and Co KG Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
WO2013169382A1 (en) * 2012-05-07 2013-11-14 DePuy Synthes Products, LLC Methods and devices for treating intervertebral disc disease
US20150166654A1 (en) 2012-05-30 2015-06-18 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
EP2893343B1 (en) 2012-09-07 2019-11-20 The Governors of the University of Alberta Methods for diagnosis of inflammatory liver disease
HK1212359A1 (en) 2012-11-01 2016-06-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質
WO2014152199A1 (en) * 2013-03-15 2014-09-25 Abbvie Inc. Antibody drug conjugate (adc) purification
CA2918795A1 (en) 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
TW202446953A (zh) 2013-12-04 2024-12-01 日商中外製藥股份有限公司 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA2938996A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the treatment of lung diseases with mast cell stabilizers
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
US10112994B2 (en) 2014-11-05 2018-10-30 Genentech, Inc. Methods of producing two chain proteins in bacteria
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
KR102456433B1 (ko) 2016-03-02 2022-10-19 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
AU2017321495A1 (en) 2016-08-31 2019-03-21 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
MX2020002667A (es) 2017-09-08 2020-08-03 Maverick Therapeutics Inc Proteinas de unión condicionalmente activadas restringidas.
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
EP3835321A4 (en) 2018-08-10 2022-11-02 Chugai Seiyaku Kabushiki Kaisha ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
CN120484127A (zh) 2019-03-05 2025-08-15 武田药品工业有限公司 受约束的条件性活化的结合蛋白
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
EP3986930A4 (en) * 2019-06-19 2023-04-12 Icahn School of Medicine at Mount Sinai Monoclonal antibodies against jc virus
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021173612A1 (en) 2020-02-26 2021-09-02 Sorrento Therapeutics, Inc. Activatable antigen binding proteins with universal masking moieties
US11338016B2 (en) 2020-05-20 2022-05-24 Howard University C-terminal fragment of tetanus toxin (Hc) for treatment of depression
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
JP2023545520A (ja) 2020-10-14 2023-10-30 ビリジアン セラピューティクス, インコーポレイテッド 甲状腺眼疾患を治療するための組成物及び方法
CN116829580A (zh) * 2020-12-15 2023-09-29 比卡拉治疗股份有限公司 用于融合蛋白的药物制剂
CN113234165B (zh) * 2021-05-07 2023-02-28 暨南大学 EpCAM的改造的结合蛋白及其应用
CN113354715B (zh) * 2021-05-07 2023-03-17 暨南大学 Egfr的改造的结合蛋白及其应用
WO2023019171A1 (en) 2021-08-10 2023-02-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CN1119415C (zh) * 1999-06-04 2003-08-27 长春迈灵生物工程有限公司 抗ca125双功能基因工程抗体的克隆与表达
JP3803790B2 (ja) * 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
EP1773881A4 (en) * 2004-05-13 2008-08-06 Imclone Systems Inc Inhibition of macrophage-stimulating protein receptor (RON)
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TWI323734B (en) * 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
CN102076355B (zh) * 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
AU2009256246B2 (en) * 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof

Similar Documents

Publication Publication Date Title
JP2012525155A5 (enExample)
JP2012525441A5 (enExample)
JP2013507969A5 (enExample)
JP2013500721A5 (enExample)
JP2013503607A5 (enExample)
JP2014504860A5 (enExample)
JP2013509189A5 (enExample)
JP2013537415A5 (enExample)
JP2013507928A5 (enExample)
RU2013133811A (ru) Иммуноглобулины с двойными вариабельными доменами и их применения
JP2013539364A5 (enExample)
JP2011523853A5 (enExample)
JP2011527580A5 (enExample)
JP2011523400A5 (enExample)
JP2012500621A5 (enExample)
RU2010153578A (ru) Иммуноглобулины с двойными вариабельными доменами и их применение
RU2011104348A (ru) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
JP2012519708A5 (enExample)
RU2015143833A (ru) СВЯЗЫВАЮЩИЕ БЕЛКИ С ДВОЙНОЙ СПЕЦИФИЧНОСТЬЮ, НАПРАВЛЕННЫЕ ПРОТИВ TNFα
WO2011163478A4 (en) Dual variable domain immunoglobulins and uses thereof
WO2012027570A4 (en) Dual variable domain immunoglobulins and uses thereof
WO2011047262A4 (en) Dual variable domain immunoglobulins and uses thereof
WO2012006490A4 (en) Dual variable domain immunoglobulins and uses thereof
WO2012018790A4 (en) Dual variable domain immunoglobulins and uses thereof
RU2461571C2 (ru) Белки, связывающие il-12/p40